文献速递血栓与止血

活动性恶性肿瘤合并孤立性浅静脉血栓形成患者的静脉血栓栓塞发生率与风险:系统综述与Meta分析(IROVAM-iSVT综述)

The incidence and risk of venous thromboembolism in patients with active malignancy and isolated superficial venous thrombosis: a systematic review and meta-analysis (the IROVAM-iSVT review).
PubMed 文献 · J Thromb Haemost · 2025-03-26

该系统综述与Meta分析检索截至2024年12月2日的Medline、Embase、Web of Science和Cochrane Library,纳入8项全文研究共5998例孤立性浅静脉血栓形成(iSVT)患者,其中448例合并活动性恶性肿瘤。癌症相关iSVT患者静脉血栓栓塞(VTE)总发生率为18.2事件/100患者年(95%CI 5.2-31.2;I²=76%),VTE风险高于无活动性恶性肿瘤的iSVT患者(风险比2.57;95%CI 1.78-3.71;I²=0%;P<.001)。

要点

  • 癌症相关iSVT患者VTE发生率为18.2事件/100患者年(95%CI 5.2-31.2;I²=76%)。
  • 癌症相关iSVT患者VTE风险约为无活动性恶性肿瘤iSVT患者的2.57倍(风险比2.57;95%CI 1.78-3.71;P<.001)。
  • 癌症相关iSVT患者大出血2事件/100患者年,全因死亡22.8事件/100患者年。

核心结论

  • 合并活动性恶性肿瘤的iSVT患者尽管接受治疗,VTE发生率仍较高。
  • 未来研究应探讨延长抗凝疗程对该人群VTE发生率的影响。

研究设计与样本

  • 系统综述与Meta分析,检索Medline、Embase、Web of Science和Cochrane Library自建库至2024年12月2日。
  • 纳入8项全文研究,共5998例iSVT患者,其中448例合并活动性恶性肿瘤。
  • 纳入标准为探讨成人iSVT合并活动性恶性肿瘤患者VTE发生率的研究。

主要发现

  • 癌症相关iSVT患者VTE总发生率为18.2事件/100患者年(95%CI 5.2-31.2;I²=76%)。
  • 癌症相关iSVT患者VTE风险高于无活动性恶性肿瘤的iSVT患者(风险比2.57;95%CI 1.78-3.71;I²=0%;P<.001)。
  • 癌症相关iSVT患者大出血发生率为2事件/100患者年(95%CI 0-6.7;I²=59%)。
  • 癌症相关iSVT患者全因死亡发生率为22.8事件/100患者年(95%CI 0-58.7;I²=73%)。
  • 仅1项研究报告了临床相关非大出血发生率和住院率。

关键数值与推荐

  • 癌症相关iSVT患者VTE发生率18.2事件/100患者年(95%CI 5.2-31.2;I²=76%)。
  • 癌症相关iSVT患者对比无活动性恶性肿瘤iSVT患者的VTE风险比2.57(95%CI 1.78-3.71;I²=0%;P<.001)。
  • 癌症相关iSVT患者大出血发生率2事件/100患者年(95%CI 0-6.7;I²=59%)。
  • 癌症相关iSVT患者全因死亡发生率22.8事件/100患者年(95%CI 0-58.7;I²=73%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • VTE发生率的Meta分析异质性I²=76%。
  • 大出血发生率的Meta分析异质性I²=59%。
  • 全因死亡发生率的Meta分析异质性I²=73%。
  • 仅1项研究报告了临床相关非大出血发生率和住院率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The management of cancer-associated isolated superficial venous thrombosis (iSVT) remains controversial as cancer patients are at higher risk of bleeding and venous thromboembolism (VTE). OBJECTIVES: We performed a systematic review and meta-analysis to determine the incidence and risk of VTE in patients with iSVT and active malignancy. METHODS: Medline, Embase, Web of Science, and the Cochrane Library were searched from inception to December 2, 2024, to identify studies investigating VTE rates in adult patients with iSVT and active malignancy. The incidence of VTE in patients with active malignancy and iSVT was pooled by meta-analysis and compared to patients with iSVT without active malignancy. Secondary outcomes included the incidence of major bleeding, clinically relevant nonmajor bleeding, hospitalization, and all-cause death. RESULTS: Eight full-text studies were included, comprising 5998 iSVT patients and 448 with active malignancy. Patients with cancer-associated iSVT had an overall incidence of VTE of 18.2 events per 100 patient years (95% CI, 5.2-31.2; I2 = 76%) and a higher rate of VTE compared to patients with iSVT without active malignancy (risk ratio, 2.57; 95% CI, 1.78-3.71; I2 = 0%; P < .001). There were 2 major bleeding events per 100 patient years (95% CI, 0-6.7; I2 = 59%) and 22.8 deaths per 100 patient years (95% CI, 0-58.7; I2 = 73%) for cancer-associated iSVT. Only 1 study reported on clinically relevant nonmajor bleeding and hospitalization rates, respectively. CONCLUSION: Patients with iSVT and active malignancy have high rates of VTE despite treatment. Future studies should investigate the role of extended duration anticoagulation on VTE rates in this population.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Bailey AJM, Luo OD, Zhou SQ, et al. The incidence and risk of venous thromboembolism in patients with active malignancy and isolated superficial venous thrombosis: a systematic review and meta-analysis (the IROVAM-iSVT review). J Thromb Haemost. 2025. PMID: 40154793. doi:10.1016/j.jtha.2025.03.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。